IDEXX Laboratories, Inc. $IDXX Stake Lifted by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,184 shares of the company’s stock after buying an additional 994 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in IDEXX Laboratories were worth $9,703,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Empowered Funds LLC boosted its stake in IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after purchasing an additional 95 shares during the period. Sivia Capital Partners LLC acquired a new position in shares of IDEXX Laboratories during the second quarter worth approximately $265,000. TD Private Client Wealth LLC increased its position in IDEXX Laboratories by 57.3% in the 2nd quarter. TD Private Client Wealth LLC now owns 225 shares of the company’s stock valued at $121,000 after acquiring an additional 82 shares during the period. Perigon Wealth Management LLC raised its stake in IDEXX Laboratories by 3.2% during the 2nd quarter. Perigon Wealth Management LLC now owns 1,458 shares of the company’s stock valued at $782,000 after acquiring an additional 45 shares in the last quarter. Finally, GC Wealth Management RIA LLC acquired a new position in IDEXX Laboratories during the 2nd quarter worth $517,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity

In other news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.98% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on IDXX shares. BTIG Research raised their price target on IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, January 12th. Barclays assumed coverage on shares of IDEXX Laboratories in a research report on Monday, December 8th. They set an “overweight” rating and a $850.00 price target on the stock. Morgan Stanley increased their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Finally, Leerink Partners set a $785.00 target price on IDEXX Laboratories in a report on Monday, November 3rd. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $763.50.

IDEXX Laboratories Stock Up 0.6%

NASDAQ IDXX opened at $697.82 on Tuesday. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The company has a market capitalization of $55.72 billion, a P/E ratio of 55.34, a PEG ratio of 3.71 and a beta of 1.67. The company’s 50 day simple moving average is $706.41 and its 200 day simple moving average is $657.44. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period last year, the firm posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.